Last reviewed · How we verify

NCT05771090: VAARA

First Clinical Evaluation of a Novel Glucose Non-invasive Sensor Technology in Patients With Type 1 Diabetes

Completed NA Last updated 29 June 2023
What this trial tests

NA trial testing Sokru device in Diabetes Mellitus in 10 participants. Completed in 16 June 2023.

Timeline
1 April 2023
Primary endpoint
16 June 2023
16 June 2023

Quick facts

Lead sponsorDCB Research AG
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposedevice feasibility
Enrollment10
Start date1 April 2023
Primary completion16 June 2023
Estimated completion16 June 2023
Sites1 location across Switzerland

Drugs / interventions tested

Conditions studied

Sponsor

DCB Research AG

Who can join

Adults 18 to 50, any sex, with Diabetes Mellitus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The primary aim of this clinical study is to find signal characteristics of VOCs detected by Sokru device during fasting, insulin injection and after glucose intake and to find the association with blood glucose variation in variant states of glycemia and hypoglycemia.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes Mellitus

Currently open trials in the same condition.

Other DCB Research AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05771090.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing